In the Clinic

Solid Tumors
Bladder Cancer

Atezolizumab in Patients With Advanced Urothelial Carcinoma Who Are Ineligible for Cisplatin

Matthew Stenger  / September 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 17, 2017, the programmed cell death ligand 1 (PD-L1) inhib...

Lymphoma

Pembrolizumab in Classical Hodgkin Lymphoma

Matthew Stenger  / September 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 14, 2017, pembrolizumab (Keytruda) was granted accel...

Leukemia

Midostaurin in FLT3 Mutation–Positive Acute Myeloid Leukemia and Systemic Mastocytosis

Matthew Stenger  / September 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. ON APRIL 28, 2017, midostaurin (Rydapt) was approved for trea...

Lung Cancer

Combination Therapy With Pembrolizumab in Metastatic Nonsquamous NSCLC

Matthew Stenger  / June 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.  On May 10, 2017, pembrolizumab (Keytruda) was granted accelerated ...

Gynecologic Cancers

Niraparib in Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Matthew Stenger  / May 25, 2017

On March 27, 2017, the oral poly ADP-ribose polymerase (PARP) inhibitor niraparib (Zejula) was approved for maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.1,2 Su...

Breast Cancer

Palbociclib Combined With Aromatase Inhibitor in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Matthew Stenger  / May 25, 2017

On March 31, 2017, palbociclib (Ibrance) was granted regular approval for treatment of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women.1,2 OF NOTE Palbociclib is an...

Lung Cancer

Osimertinib in Metastatic EGFR T790M–Mutant NSCLC After EGFR Inhibitor Therapy

Matthew Stenger  / May 25, 2017

Osimertinib in <em>EGFR</em> T790M–Mutant Lung Cancer Osimertinib (Tagrisso) was granted regular approval for the treatment of patients with metastatic epidermal growth factor receptor (EGFR ) T790M–mutant NSCLC who have progressed on or after EGFR tyrosine kinase inhibitor th...

Skin Cancer

Avelumab in Merkel Cell Carcinoma

Matthew Stenger  / May 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 23, 2017, avelumab (Bavencio) was granted accelerated...

Multiple Myeloma

Lenalidomide as Maintenance Therapy in Multiple Myeloma After Autologous Stem Cell Transplantation

Matthew Stenger  / May 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 22, lenalidomide (Revlimid) was approved as mainte...

Bladder Cancer

Nivolumab in Urothelial Carcinoma After Platinum Therapy

Matthew Stenger  / April 25, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 2, 2017, nivolumab (Opdivo) was granted accelerate...

Breast Cancer

Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

Matthew Stenger  / April 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 13, the cyclin-dependent kinase (CDK) 4/6 inhibi...

Lymphoma

Ibrutinib in Marginal Zone Lymphoma

Matthew Stenger  / March 10, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 19, ibrutinib (Imbruvica) was granted accelera...

Gynecologic Cancers

Rucaparib in Previously Treated BRCA Mutation–Associated Ovarian Cancer

Matthew Stenger  / January 25, 2017

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 19, 2016, rucaparib (Rubraca) was granted accelera...

Multiple Myeloma

Daratumumab in Previously Treated Multiple Myeloma

Matthew Stenger  / December 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 21, 2016, daratumumab (Darzalex) was approved for ...

Head and Neck Cancer

Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Matthew Stenger  / December 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 10, 2016, nivolu­mab (Opdivo) was approved for tre...

Lung Cancer

Pembrolizumab in First-Line Treatment of Metastatic Non–Small Cell Lung Cancer

Matthew Stenger  / November 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 24, 2016, pembrolizumab (Keytruda) was approved for...

Lung Cancer

Atezolizumab in Previously Treated Metastatic NSCLC

Matthew Stenger  / November 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 18, 2016, the anti–PD-L1 (programmed cell death lig...

Lung Cancer

Modified Indication for Erlotinib in Advanced Non–Small Cell Lung Cancer

Matthew Stenger  / November 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 18, 2016, the indication for erlotinib (Tarceva) in...

Sarcoma

Olaratumab in Soft-Tissue Sarcoma

Matthew Stenger  / November 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 19, 2016, the platelet-derived growth factor recept...

Lung Cancer
Skin Cancer
Kidney Cancer

Modification of Dosage Regimen for Nivolumab in Renal Cell Carcinoma, Melanoma, and NSCLC

Matthew Stenger  / October 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 13, 2016, the U.S. Food and Drug Administration modifi...

Head and Neck Cancer

Use of Pembrolizumab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma After Platinum-Containing Therapy

Matthew Stenger  / September 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 5, 2016, pembrolizumab (Keytruda) was granted accele...

Lymphoma

Nivolumab in Classical Hodgkin Lymphoma

Matthew Stenger  / June 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 17, 2016, nivolumab (Opdivo) was granted accelerated ap...

Bladder Cancer

PD-L1 Inhibitor Atezolizumab for Locally Advanced or Metastatic Urothelial Carcinoma

Matthew Stenger  / June 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.On May 18, 2016, the PD-L1 (programmed cell death ligand 1) inhibitor...

Kidney Cancer

Lenvatinib in Combination With Everolimus in Advanced Renal Cell Carcinoma

Matthew Stenger  / June 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 13, 2016, lenvatinib (Lenvima) was approved for use in combi...

Leukemia

Venetoclax for Previously Treated Chronic Lymphocytic Leukemia With 17p Deletion

Matthew Stenger  / May 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 11, 2016, venetoclax ­(Venclexta) was approved for tr...

Kidney Cancer

Cabozantinib in Advanced Renal Cell Carcinoma

Matthew Stenger  / May 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 25, 2016, a tablet formulation of cabozantinib (Cabometyx...

Solid Tumors

Relatives of Patients With Carcinoma of Unknown Primary at Increased Risk for This and Other Cancers

Charlotte Bath  / May 25, 2016

Relatives of patients with carcinoma of unknown primary are at increased risk of developing this type of cancer themselves and several other malignant neoplasms, including lung, pancreatic, and colon cancers; non-Hodgkin lymphoma; and myeloma, according to a study published in JAMA Oncology. “Some o...

Symptom Management

Defibrotide Sodium for Hepatic Veno-occlusive Disease After HSCT

Matthew Stenger  / May 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 30, 2016, defibrotide sodium (Defitelio) was approved for ...

Lung Cancer

Crizotinib in ROS1-Positive Metastatic Non–Small Cell Lung Cancer

Matthew Stenger  / April 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 11, 2016, crizotinib (Xalkori) was approved for treat...

Solid Tumors

Everolimus in Advanced Neuroendocrine Tumors

Matthew Stenger  / March 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 26, 2016, everolimus (Afinitor) was approved for t...

Breast Cancer

Palbociclib Combined With Fulvestrant in Advanced Breast Cancer Progressing After Endocrine Therapy

Matthew Stenger  / March 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 19, 2016, palbociclib (Ibrance) was approved for u...

Lymphoma

Obinutuzumab in Relapsed or Refractory Follicular Lymphoma

Matthew Stenger  / March 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 26, 2016, obinutuzumab (Gazyva) was approved for u...

Hematologic Malignancies
Multiple Myeloma

Carfilzomib Plus Dexamethasone in Previously Treated Multiple Myeloma

Matthew Stenger  / March 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 21, 2016, carfilzomib (Kyprolis) was approved for use in...

Sarcoma

Eribulin Mesylate in Advanced Liposarcoma Previously Treated With an Anthracycline

Matthew Stenger  / March 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 28, 2016, eribulin mesylate (Halaven) was approved for t...

Leukemia

Ofatumumab for Extended Treatment of Patients With Recurrent or Progressive Chronic Lymphocytic Leukemia

Matthew Stenger  / February 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 19, 2016, ofatumumab (Arzerra) was approved for ext...

Skin Cancer

Nivolumab Plus Ipilimumab in Unresectable or Metastatic Melanoma Regardless of BRAF Mutation Status

Matthew Stenger  / February 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On January 23, 2016, the indication for nivolumab (Opdivo) plu...

Skin Cancer

Expanded Approval of Pembrolizumab in Unresectable or Metastatic Melanoma

Matthew Stenger  / February 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On December 18, 2015, approval of the programmed cell death prot...

Lung Cancer

Alectinib in ALK-Positive Metastatic NSCLC After Crizotinib

Matthew Stenger  / February 10, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On December 11, 2015, alectinib (Alecensa) was granted accelerat...

Multiple Myeloma

Elotuzumab in Previously Treated Multiple Myeloma

Matthew Stenger  / January 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On November 30, 2015, elotuzu­mab (Empliciti) was approved for u...

Supportive Care

Uridine Triacetate Granules for Fluorouracil or Capecitabine Overdose or Early Severe Toxicity

Matthew Stenger  / January 25, 2016

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 11, 2015, uridine triacetate (Vistogard) was approved...

Kidney Cancer

Nivolumab in Advanced Renal Cell Carcinoma After Antiangiogenic Therapy

Matthew Stenger  / December 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On November 23, 2015, nivolumab (Opdivo) was approved for use in...

Skin Cancer

Nivolumab as Single-Agent Treatment for BRAF V600 Wild-Type Unresectable or Metastatic Melanoma

Matthew Stenger  / December 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On November 24, 2015, nivolumab (Opdivo) was approved for use as...

Lung Cancer

Necitumumab in Metastatic Squamous Non–Small Cell Lung Cancer

Matthew Stenger  / December 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 24, 2015, necitumumab (Portrazza) was approved for us...

Skin Cancer

Cobimetinib in BRAF-Mutant Unresectable or Metastatic Melanoma in Combination With Vemurafenib

Matthew Stenger  / December 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs On November 10, 2015, the U.S. Food and Drug Administration approv...

Lung Cancer

Osimertinib for Metastatic EGFR T790M–Mutant Non–Small Cell Lung Cancer After EGFR Inhibitor Therapy

Matthew Stenger  / December 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 13, 2015, osimertinib (Tagrisso) was granted accelerate...

Multiple Myeloma

Daratumumab in Previously Treated Multiple Myeloma

Matthew Stenger  / December 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On November 16, 2015, daratumumab injection (Darzalex) was grant...

Multiple Myeloma

Ixazomib in Previously Treated Multiple Myeloma

Matthew Stenger  / December 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 20, 2015, ixazomib (Ninlaro) was approved by the U.S. F...

Skin Cancer

Ipilimumab in Adjuvant Treatment of Cutaneous Melanoma With Nodal Involvement

Matthew Stenger  / November 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 28, 2015, ipilimumab (Yervoy) was approved for adjuvan...

Skin Cancer

Talimogene Laherparepvec for Treatment of Unresectable Cutaneous, Subcutaneous, and Nodal Melanoma Lesions

Matthew Stenger  / November 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 27, 2015, talimogene laherparepvec (Imlygic) was appro...

Sarcoma

Trabectedin in Unresectable or Metastatic Liposarcoma or Leiomyosarcoma

Matthew Stenger  / November 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 23, 2015, trabectedin (Yondelis) was approved for the ...

Pancreatic Cancer

Irinotecan Liposome Injection Plus Fluorouracil/Leucovorin to Treat Patients With Metastatic Pancreatic Cancer

Matthew Stenger  / November 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On October 22, 2015, irinotecan liposome injection (Onivyde) giv...

Lung Cancer

Nivolumab in Metastatic NSCLC After Platinum Therapy

Matthew Stenger  / November 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 9, 2015, the anti–programmed cell death protein 1 (PD-...

Skin Cancer

Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma

Matthew Stenger  / October 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 30, 2015, the U.S. Food and Drug Administration gran...

Lung Cancer

Pembrolizumab in Previously Treated PD-L1–Positive Metastatic NSCLC

Matthew Stenger  / October 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On October 2, 2015, the U.S. Food and Drug Administration granted...

Symptom Management

Rolapitant for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting

Matthew Stenger  / September 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 2, 2015, rolapitant (Varubi) was approved for use in c...

Lymphoma

Brentuximab Vedotin for Consolidation Therapy in High-Risk Hodgkin Lymphoma

Matthew Stenger  / September 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On August 17, 2015, brentuximab vedotin (Adcetris) was approved ...

Lung Cancer

Gefitinib in EGFR-Mutant Metastatic NSCLC

Matthew Stenger  / August 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 13, 2015, gefitinib (Iressa) was approved for first-line ...

Multiple Myeloma

Carfilzomib in Combination With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma

Matthew Stenger  / August 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On July 24, 2015, carfilzomib (Kyprolis) was approved for use in...

Skin Cancer

Sonidegib in Basal Cell Carcinoma

Matthew Stenger  / August 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On July 24, 2015, sonidegib (Odomzo) was approved for treatment o...

Colorectal Cancer

Ramucirumab With FOLFIRI in Metastatic Colorectal Cancer

Matthew Stenger  / May 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 24, the monoclonal antibody ramucirumab ­(Cyramza) was app...

CNS Cancers

Dinutuximab in Pediatric High-Risk Neuroblastoma

Matthew Stenger  / April 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On March 10, 2015, the chimeric monoclonal antibody dinutuximab ...

Issues in Oncology
Supportive Care

Biosimilar Filgrastim-sndz in Filgrastim Indications

Matthew Stenger  / April 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On March 6, 2015, the granulocyte colony-stimulating factor filg...

Lung Cancer

Nivolumab in Metastatic Squamous Non–Small Cell Lung Cancer After Platinum Therapy

Matthew Stenger  / April 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On March 4, 2015, the anti–programmed cell death protein 1 (PD-1...

Multiple Myeloma

Lenalidomide in Combination With Dexamethasone in Newly Diagnosed Multiple Myeloma

Matthew Stenger  / March 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On February 18, 2015, the indication for lenalidomide (Revlimid)...

Multiple Myeloma

Panobinostat in Combination With Bortezomib‑Dexamethasone in Previously Treated Multiple Myeloma

Matthew Stenger  / March 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On February 23, 2015, panobinostat (Farydak) was granted acceler...

Thyroid Cancer

Lenvatinib in Advanced Radioiodine-Refractory Differentiated Thyroid Cancer

Matthew Stenger  / March 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On February 13, 2015, lenvatinib (Lenvima) was approved for the ...

Breast Cancer

Palbociclib as Initial Endocrine-Based Therapy in Postmenopausal Women With Metastatic Breast Cancer

Matthew Stenger  / March 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On February 3, 2015, palbociclib (Ibrance) was granted accelerat...

Hematologic Malignancies

Ibrutinib for Waldenström’s Macroglobulinemia

The ASCO Post  / February 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On January 29, 2015, the U.S. Food and Drug Administration (FDA)...

Leukemia

Blinatumomab in Philadelphia Chromosome–Negative Relapsed/Refractory B-Cell Precursor ALL

The ASCO Post  / February 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 3, 2014, blinatumomab (Blincyto) was granted accelerate...

Hematologic Malignancies

Ruxolitinib for Polycythemia Vera

Matthew Stenger  / February 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 4, 2014, ruxolitinib (Jakafi) was approved for the trea...

Lung Cancer

Ramucirumab in Metastatic Non–Small Cell Lung Cancer

Matthew Stenger  / February 10, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. In December 12, 2014, ramucirumab (Cyramza) was approved for use in...

Skin Cancer

Anti–PD-1 Antibody Nivolumab in Previously Treated Unresectable or Metastatic Melanoma

Matthew Stenger  / January 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On December 22, 2014, the anti–PD-1 (programmed cell death prote...

Neuroendocrine Tumors

Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors

Matthew Stenger  / January 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On December 16, 2014, lanreotide (Somatuline depot injection) wa...

Gynecologic Cancers

Gardasil 9 Adds Protection Against Cancer Caused by Additional Human Papillomavirus Types

Matthew Stenger  / January 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On December 10, 2014, Gardasil 9 (human papillomavirus 9-valent ...

Gynecologic Cancers

Olaparib for BRCA-Mutated Previously Treated Advanced Ovarian Cancer

Matthew Stenger  / January 25, 2015

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 19, 2014, olaparib (Lynparza) was granted accelerated a...

Bevacizumab Plus Chemotherapy in Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

The ASCO Post  / December 1, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On November 14, 2014, bevacizumab (Avastin) in combination with pac...

Lymphoma

Bortezomib in Previously Untreated Mantle Cell Lymphoma

Matthew Stenger  / November 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On October 9, 2014, bortezomib (Velcade) was granted approval fo...

Supportive Care

Fixed-Combination Netupitant/Palonosetron for Prevention of Chemotherapy-Induced Nausea and Vomiting

Matthew Stenger  / November 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On October 10, 2014, oral fixed-combination netupitant and palon...

Gastroesophageal Cancer

Ramucirumab in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Matthew Stenger  / November 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On November 5, 2014, ramucirumab (Cyramza) was approved for use ...

Skin Cancer

First Approval of PD-1 Inhibitor: Pembrolizumab in Unresectable or Metastatic Melanoma

Matthew Stenger  / October 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On September 4, 2014, pembrolizumab (Keytruda) was granted accel...

Prostate Cancer

Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Matthew Stenger  / October 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On September 10, 2014, the androgen receptor inhibitor enzalutam...

Multiple Myeloma

Bortezomib Retreatment in Multiple Myeloma

Matthew Stenger  / September 1, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On August 8, 2014, the approved use of bortezomib (Velcade) in mult...

Gynecologic Cancers

Bevacizumab in Persistent, Recurrent, or Metastatic Cervical Cancer

Matthew Stenger  / September 1, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On August 14, 2014, bevacizumab (Avastin) was approved for the t...

Leukemia
Lymphoma

Idelalisib for Relapsed CLL in Combination With Rituximab and for Relapsed Follicular Lymphoma or Small Lymphocytic Lymphoma

Matthew Stenger  / August 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On July 23, 2014, idelalisib (Zydelig) was approved for  use in ...

Leukemia

Ibrutinib in Previously Treated CLL and CLL With 17p Deletion

Matthew Stenger  / August 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On July 28, 2014, the approved use of ibrutinib (Imbruvica) in p...

Lymphoma

Belinostat for Relapsed/Refractory Peripheral T-Cell Lymphoma

Matthew Stenger  / July 25, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On July 3, 2014, belinostat (Beleodaq) was granted accelerated ...

Colorectal Cancer

Panitumumab Plus FOLFOX for KRAS Wild-Type Metastatic Colorectal Cancer

Matthew Stenger  / July 10, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Panitumumab (Vectibix) was recently approved by the U.S. Food and D...

Hematologic Malignancies

Siltuximab for Multicentric Castleman’s Disease

Matthew Stenger  / July 10, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 23, 2014, the anti–interleukin (IL)-6 monoclonal antibody ...

Leukemia

Mercaptopurine Oral Suspension for Acute Lymphoblastic Leukemia

Matthew Stenger  / June 10, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   On April 28, 2014, an oral suspension of mercaptopurine (Purixan...

Lung Cancer

Ceritinib in ALK-Positive Metastatic NSCLC Patients With Progression on or Intolerance to Crizotinib

Matthew Stenger  / June 10, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 29, 2014, ceritinib (Zykadia) was granted accelerated appr...

Leukemia

Ofatumumab Plus Chlorambucil for Previously Untreated CLL in Patients Not Treatable With Fludarabine-Based Regimens

Matthew Stenger  / May 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On April 17, 2014, ofatumumab (Arzerra) received regular approval f...

Gastroesophageal Cancer

Ramucirumab for Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Matthew Stenger  / May 15, 2014

On April 21, 2014, ramucirumab (Cyramza) was approved for use as a single agent in the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine- or platinum-containing chemotherapy...

Leukemia

Ibrutinib for Previously Treated Chronic Lymphocytic Leukemia

Matthew Stenger  / March 15, 2014

On February 12, 2014, ibrutinib (Imbruvica) was granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.1,2 Ibrutinib previously received accelerated approval for the treatment of patients with mantle cell lympho...

Skin Cancer

Trametinib and Dabrafenib in Combination for Unresectable or Metastatic Melanoma With BRAF V600E or V600K Mutations

Matthew Stenger  / February 15, 2014

On January 9, 2014, the combination of trametinib (Mekinist) and dabrafenib (Tafinlar) was granted accelerated approval for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2...

Multiple Myeloma

Ongoing NCI-Funded Clinical Trials Actively Recruiting Patients With Hematologic Cancers: Multiple Myeloma

Jo Cavallo  / February 15, 2014

Study Type: Non-Randomized Phase I/Interventional Study Title: Multicenter Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in High-Risk Multiple Myeloma Study Sponsor and Collaborators: National Cancer Institute; Hackensack University Medic...

Thyroid Cancer

Sorafenib in Differentiated Thyroid Carcinoma

Matthew Stenger  / January 15, 2014

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. New Indication On November 22, 2013, sorafenib (Nexavar) was appro...

Lymphoma

Ibrutinib in Previously Treated Mantle Cell Lymphoma

Matthew Stenger  / December 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On November 13, 2013, ibrutinib (Imbruvica) was granted...

Leukemia

Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Matthew Stenger  / December 1, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On November 1, 2013, obinutuzumab (Gazyva) was approved...

Breast Cancer

Pertuzumab in Neoadjuvant Treatment of HER2-Positive Early Breast Cancer

Matthew Stenger  / November 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On September 30, 2013, pertuzumab injection (Perjeta) w...

Pancreatic Cancer

Nab-Paclitaxel in Metastatic Pancreas Cancer 

Matthew Stenger  / November 1, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On September 6, paclitaxel protein-bound particles [alb...

Lung Cancer

Afatinib as First-line Treatment for Metastatic NSCLC with EGFR Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations 

Matthew Stenger  / August 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On July 12, 2013, afatinib (Gilotrif) was approved for ...

Lymphoma

Lenalidomide in Relapsed/Progressed Mantle Cell Lymphoma after Two Prior Therapies Including Bortezomib 

Matthew Stenger  / July 25, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On June 5, 2013, lenalidomide (Revlimid) was approved f...

Prostate Cancer

Radium-223 Dichloride for Castration-resistant Prostate Cancer with Symptomatic Bone Metastases 

Matthew Stenger  / July 10, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 15, 2013, radium Ra 223 dichloride (Xofigo) was ...

Lung Cancer

Erlotinib in First-line Treatment of Metastatic NSCLC with EGFR Exon 19 Deletion or Exon 21 (L858R) Substitution 

Matthew Stenger  / July 10, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.   Indication On May 14, 2013, erlotinib (Tarceva) was approved for...

Skin Cancer

Dabrafenib for Unresectable or Metastatic Melanoma with BRAF V600E Mutation 

Matthew Stenger  / June 25, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.  Indication On May 29, 2013, dabrafenib (Tafinlar) was approved fo...

Skin Cancer

Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation

The ASCO Post  / June 25, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was approved by ...

Breast Cancer

Ado-Trastuzumab Emtansine in Metastatic Breast Cancer 

Matthew Stenger  / April 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.  Indication On February 22, 2013, ado-trastuzumab emtansine (Kadcy...

Hematologic Malignancies
Issues in Oncology

Pomalidomide in Previously Treated Multiple Myeloma 

Matthew Stenger  / March 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On February 8, 2013, the immunomodulatory agent pomalid...

Colorectal Cancer

Bevacizumab plus Chemotherapy after Progression of Metastatic Colorectal Cancer on First-line Therapy Including Bevacizumab 

Matthew Stenger  / March 1, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On January 23, 2013, bevacizumab (Avastin) was approved...

Prostate Cancer

Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer and No Prior Chemotherapy

Matthew Stenger  / February 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On December 10, 2012, abiraterone acetate (Zytiga) rece...

Leukemia

Ponatinib in Chronic Myeloid Leukemia and Philadelphia Chromosome–positive Acute Lymphoblastic Leukemia 

Matthew Stenger  / February 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On December 14, 2012, ponatinib (Iclusig) was granted a...

Thyroid Cancer

Cabozantinib in Metastatic Medullary Thyroid Cancer 

Matthew Stenger  / February 1, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs.  Indication On November 29, 2012, cabozantinib (Cometriq) was appr...

Leukemia

Omacetaxine for Chronic or Accelerated Phase CML Patients with Resistance/Intolerance to Tyrosine Kinase Inhibitors

Matthew Stenger  / January 15, 2013

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On October 26, 2012, the FDA granted accelerated approv...

Hematologic Malignancies
Leukemia

Liposomal Vincristine for Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Matthew Stenger  / December 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In August 2012, vinCRIStine sulfate LIPOSOME injection ...

Hematologic Malignancies
Leukemia

SIDEBAR: REPORT ADVERSE EVENTS

Matthew Stenger  / December 15, 2012

Health-care professionals should report all serious adverse events suspected to be associated with the use of any medicine or device to FDA’s MedWatch Reporting System by completing a form online at http://www.fda.gov/medwatch/report.htm, by faxing (1-800-FDA-0178), by mailing the postage-paid addre...

CNS Cancers

Revised Everolimus Dosing and New Safety/Efficacy Data for Approval in Subependymal Giant Cell Astrocytoma

Matthew Stenger  / December 15, 2012

On August 29, 2012, everolimus in a tablet for oral suspension form (Afinitor Disperz) was given accelerated approval for the treatment of pediatric and adult patients with tuberous sclerosis complex who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but canno...

Regorafenib, Multikinase Inhibitor, for Previously Treated Metastatic Colorectal Cancer

Matthew Stenger  / November 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On September 27, 2012, regorafenib (Stivarga) was appro...

Albumin-bound Paclitaxel in First-line Treatment of Advanced NSCLC

Matthew Stenger  / November 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On October 11, 2012, paclitaxel protein-bound particles...

Ruxolitinib: Novel Drug for Myelofibrosis

Matthew Stenger  / November 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In November 2011, ruxolitinib (Jakafi) was approved for...

Skin Cancer

Vismodegib: Novel Agent for Treating Advanced Basal Cell Carcinoma

Matthew Stenger  / November 1, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In January 2012, vismodegib (Erivedge) was approved for...

Leukemia

Bosutinib in Chronic Myelogenous Leukemia Patients with Resistance or Intolerance of Prior Therapy

Matthew Stenger  / October 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In September 4, 2012, bosutinib (Bosulif) was approved ...

Prostate Cancer

Enzalutamide for Metastatic Castrate-resistant Prostate Cancer

Matthew Stenger  / October 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In August 31, enzalutamide (Xtandi) was approved for th...

Colorectal Cancer

New Indication for Cetuximab plus FOLFIRI to Treat EGFR-positive, Wild-type KRAS Metastatic Colorectal Cancer

Matthew Stenger  / September 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In July 2012, cetuximab (Erbitux) was approved for use ...

Ziv-aflibercept with FOLFIRI in Metastatic Colorectal Cancer

Matthew Stenger  / September 15, 2012

In August 2012, the antiangiogenic agent ziv-aflibercept (Zaltrap) was approved for use in combination with FOLFIRI (fluorouracil, leucovorin, irinotecan) for the treatment of metastatic colorectal cancer resistant to or progressing after an oxaliplatin-containing regimen.1,2 Approval was based on ...

Multiple Myeloma

Carfilzomib: New Drug with Accelerated Approval for Multiple Myeloma

Matthew Stenger  / September 1, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In July 2012, carfilzomib (Kyprolis) was granted accele...

Breast Cancer

Pertuzumab: New Drug for HER2-positive Metastatic Breast Cancer

Matthew Stenger  / August 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In June 2012, pertuzumab (Perjeta) was approved for use...

Sarcoma

Pazopanib: New Drug for Advanced Soft-tissue Sarcoma

Matthew Stenger  / July 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In April 2012, pazopanib (Votrient) was approved for th...

Everolimus: New Indication in Renal Angiomyolipoma Associated with Tuberous Sclerosis Complex

Matthew Stenger  / July 1, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In April 2012, the kinase inhibitor everolimus (Afinito...

Lymphoma

Newest Indication for Rituximab as Maintenance Treatment in Non‑Hodgkin Lymphoma

Matthew Stenger  / June 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication The CD20-directed monoclonal antibody rituximab (Rituxa...

What You Need to Know About Glucarpidase Injection for Toxic Methotrexate Levels in Renal Impairment

Matthew Stenger  / June 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In January 2012, glucarpidase injection (Voraxaze) was ...

Thyroid Cancer

Vandetanib: New Drug for Unresectable Medullary Thyroid Cancer

Matthew Stenger  / May 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication The oral kinase inhibitor vandetanib (Caprelsa) was rec...

Solid Tumors

Using Imatinib for Adjuvant Treatment after Resection of Kit (CD117)-positive Gastrointestinal Stromal Tumors

Matthew Stenger  / May 1, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In January 2012, imatinib mesylate (Gleevec) was grante...

Leukemia

Erwinia chrysanthemi Asparaginase for Acute Lymphoblastic Leukemia in Patients with Hypersensitivity to E coli–derived Asparaginase

Matthew Stenger  / April 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication Erwinia chrysanthemi asparaginase (Erwinaze) was recent...

Kidney Cancer

What You Need to Know About Axitinib, New Agent for Treating Advanced Renal Cell Carcinoma

Matthew Stenger  / March 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication In January 2012, the second-generation vascular endothe...

Skin Cancer

What You Should Know about Peginterferon Alfa-2b for Adjuvant Treatment of Melanoma

Matthew Stenger  / March 1, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication Peginterferon alfa-2b (PegIntron, Sylatron) was recentl...

Prostate Cancer

Abiraterone: New Drug in the Treatment of Metastatic Castration-resistant Prostate Cancer

Matthew Stenger  / February 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication Abiraterone acetate (Zytiga) (an oral agent that inhibi...

Breast Cancer
Prostate Cancer

What You Should Know about Denosumab (Prolia) for Increasing Bone Mass during Breast and Prostate Cancer Therapies

Matthew Stenger  / January 15, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indications In September 2011, the monoclonal antibody RANKL inhib...

Head and Neck Cancer

New Indication for Cetuximab in Squamous Cell Carcinoma of the Head and Neck

Matthew Stenger  / January 1, 2012

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Cetuximab (Erbitux) was recently approved by the FDA for use in com...

Skin Cancer

Gathering Data Point to Potential Advantages of Vismodegib in Basal Cell Carcinoma and Other Advanced Cancers

Matthew Stenger  / December 15, 2011

Vismodegib is a small-molecule, orally active hedgehog pathway inhibitor that has shown considerable promise in treating basal cell carcinoma and is currently being evaluated alone and in combination in early-phase trials in medulloblastoma and a long list of other cancers.1 Owing to its first-in-cl...

Solid Tumors

Sunitinib and Everolimus: New Indications in Pancreatic Neuroendocrine Tumors

Matthew Stenger  / November 15, 2011

With In the Clinic, The ASCO Post provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Sunitinib Indication—The oral kinase inhibitor...

Lung Cancer

Crizotinib: New Drug for ALK-positive Advanced Non–Small Cell Lung Cancer

Matthew Stenger  / November 1, 2011

Indication Crizotinib (Xalkori) is an oral inhibitor of receptor tyrosine kinases including anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-Met), and recepteur d’origine nantais (RON). In August 2011, the FDA granted the drug accelerated approval for the treatment of pa...

Skin Cancer

Novel Drugs Ipilimumab and Vemurafenib for Advanced Melanoma

Matthew Stenger  / October 15, 2011

In this introductory installment of In the Clinic, The ASCO Post provides an overview of two new melanoma agents recently approved by FDA, with discussion on pivotal data leading to approval, dosage and administration, and managing drug-related toxicities. Watch for more on clinical use of novel onc...

Advertisement

Advertisement



Advertisement